Right Now
The Critical Limb Ischemia Treatment Market is
Anticipated to Witness High Growth Owing to Rising Prevalence of Risk Factors
for Peripheral Artery Disease
The critical limb ischemia treatment market comprises
medical devices and drugs utilized for the treatment of severe obstruction of
large arteries that supply blood to leg and foot muscles. Critical limb ischemia
is a serious condition where there is reduction of blood flow to the limbs,
which could further lead to tissue damage, infection or non-healing ulcers and
may require amputation of the affected limb in severe cases. Various measures
are taken to restore blood flow in the arteries of the limbs such as balloon
angioplasty, stenting and surgical bypass procedures that utilize prosthetic
grafts or the patient's own veins. Drugs such as antiplatelets, anticoagulants
and fibrinolytics are also administered to reduce the risk of arterial blockage
and improve blood flow. The rising prevalence of risk factors such as smoking,
diabetes, obesity, high blood pressure and high cholesterol levels that
increase the likelihood of peripheral artery disease has driven the need for
effective critical limb ischemia treatments.
The Global
Critical Limb Ischemia Treatment Market is estimated to be valued at US$ 9.11
Bn in 2024 and is expected to exhibit a CAGR of 8.5% over the forecast period
2024 to 2031.
Key Takeaways
Key players operating in the Critical
Limb Ischemia Treatment Market Companies are Medtronic plc, Boston
Scientific Corporation, Abbott Laboratories, Cook Medical Inc., Cardiovascular
Systems, Inc., Philips Healthcare, B. Braun Melsungen AG, Terumo Corporation,
Biotronik SE & Co. KG, Cordis Corporation, Smith & Nephew plc, Stryker
Corporation, AngioDynamics, Inc., GE Healthcare, Sanofi S.A., AstraZeneca plc,
and Bristol-Myers Squibb Company. These players are focusing on developing
innovative drug-eluting stents, imaging systems and devices to aid endovascular
procedures.
The key opportunities in the market include rising investments in research and
development of advanced drug therapies and minimally invasive procedures for
critical limb ischemia. The market players are also expanding their presence in
emerging markets through partnerships and collaborations to cater to the
increasing disease burden in Asia Pacific, Latin America, Middle East and
Africa.
The global expansion of major players through acquisitions has further aided
their presence across various countries. For instance, Medtronic acquired Mazor
Robotics to expand its surgical robotic technologies portfolio whereas Stryker
acquired Orbital Atherectomy System to enhance its peripheral vascular
products.
Market drivers and restrain
The rising geriatric population susceptible to peripheral artery disease
and limited mobility is a major driver for the Critical
Limb Ischemia Treatment Market Growth. With ageing, arteries tend to
narrow down restricting blood flow to limbs. According to estimates by 2050,
over 16% of the world's population will be aged over 65 years. This expanding
geriatric demographic presents a steady source of patients requiring critical
limb ischemia treatments.
Market key restrain:
High cost of treatment procedures and devices is a major challenge
hampering the growth of critical limb ischemia treatment market. Surgical
bypass procedures utilizing prosthetic grafts require advanced medical
infrastructure and cost in range of tens of thousands of dollars rendering it
unaffordable for many. Even drug therapy entails lifelong treatment involving
substantial costs. This cost burden acts as a restraint particularly in low and
middle-income countries.
Segment Analysis
The critical limb ischemia treatment market is segmented into drug therapy,
angioplasty, bypass surgery, thrombolytic therapy, and amputation. The drug
therapy segment is expected to dominate the market during the forecast period.
Drug therapy is dominating because it helps reduce pain and heal ulcers by
improving blood circulation to the affected areas. Antiplatelet drugs, statins,
alpha and beta blockers, and calcium channel blockers are commonly prescribed
for drug therapy, as they are minimally invasive and provide effective relief
from symptoms.
Global Analysis
On the basis of regions, North America is expected to hold the largest
share of the Critical Limb Ischemia
Treatment Market Challenges during the forecast period. This is mainly due
to the growing prevalence of peripheral artery disease, developed healthcare
infrastructure, raising awareness about treatment options and favorable
reimbursement policies in the region. Asia Pacific is projected to grow at the
highest CAGR during the same period owing to improving healthcare facilities,
rising geriatric population, increasing adoption of advanced treatment options
and medical tourism in China, Japan and India.
Get more insights on Critical
Limb Ischemia Treatment Market
For
Deeper Insights, Find the Report in the Language that You want
About Author
Alice Mutum, is a seasoned senior
content editor at Coherent Market Insights, leveraging extensive expertise
gained from her previous role as a content writer. With seven years in content
development, Alice masterfully employs SEO best practices and cutting-edge
digital marketing strategies to craft high-ranking, impactful content. As an
editor, she meticulously ensures flawless grammar and punctuation, precise data
accuracy, and perfect alignment with audience needs in every research report.
Alice's dedication to excellence and her strategic approach to content make her
an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
More Posts
Report This Post
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.
